Clemizole, sold under the brand names Allercur and Histacur, is a histamine H1 receptor antagonist of the benzimidazole group described as an antihistamine, antipruritic, and sedative which is no longer marketed. It is a first-generation antihistamine.
Clemizole, sold under the brand names Allercur and Histacur, is a histamine H1 receptor antagonist of the benzimidazole group described as an antihistamine, antipruritic, and sedative which is no longer marketed. It is a first-generation antihistamine.
It is also a serotonin receptor agonist and is being studied for the potential treatment of Dravet syndrome, Lennox–Gastaut syndrome, and epilepsy under the development code name EPX-100. The drug is said to act specifically as a serotonin 5-HT2 receptor agonist, with prominent affinity for the serotonin 5-HT2A and 5-HT2B receptors having been reported. On the other hand, it showed markedly lower affinity for the serotonin 5-HT2C receptor. Clemizole also showed affinity for several other receptors.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).